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Healthy aims: 
Developing new medical 
implants and Diagnostic 
equipment
A European Union project consortium is developing intelligent medical 
implants and diagnostic systems that integrate a range of underpinning 
microprocessor, biological, wireless, and nano technologies.
H ealthy Aims is a €23-mill ion, four-year project, funded under the EU’s Information Society Technology 
Sixth Framework program to develop 
intelligent medical implants and diag-
nostic systems (www.healthyaims.
org). The project has 25 partners from 
10 countries, including commercial, 
clinical, and research groups. This 
consortium represents a combination 
of disciplines to design and fabricate 
new medical devices and components 
as well as to test them in laboratories 
and subsequent clinical trials.
The project focuses on medical 
implants for nerve stimulation and 
diagnostic equipment based on strain-
gauge technology. Figure 1 shows sev-
eral products in development:
a retinal implant for restoration of 
sight,
functional electrical stimulation 
(FES) systems for restoration of 
upper-limb movement as well as 
bladder and bowel control,
a cochlear implant for restoration of 
•
•
•
hearing,
a glaucoma sensor for diagnosing 
glaucoma,
an intracranial pressure (ICP) sensor 
system for monitoring brain pressure,
a sphincter sensor for monitoring 
bladder pressure, and
an activity monitor and laboratory 
system for accurate interpretation of 
human motion.
These products have clear market appli-
cations, targeting citizens suffering 
from disabilities that affect their quality 
of life—for example, blindness, stroke 
disabilities, deafness, and incontinence. 
With an estimated 500 million citizens 
in the Western population suffering 
from at least one of the health problems 
targeted in this project, the potential 
market and impact on society are huge.
Healthy Aims has also developed core 
technologies in parallel with the prod-
ucts with a view to stimulating future 
medical-implant technology. These 
include implantable power sources, RF 
communications suitable for implant-
ing in the human body, and biocompat-
ible encapsulation materials.
•
•
•
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status of project products
Now in its final year, the Healthy Aims 
projects have achieved some remarkable 
results in product development.
retinal implant
The retinal implant system is suitable 
for patients suffering from retinitis pig-
mentosa, cone-rod dystrophy, and mac-
ular degeneration. All these diseases 
include progressive degeneration of the 
photoreceptors, which leads to com-
plete blindness. However, the retinal 
ganglion cell layer often remains intact. 
The implant system uses this layer as 
the basis for conducting nerve signals 
to the brain’s visual areas.1
The system consists of three main 
components: 
the retinal stimulator, which is im-
 planted in the eye;
the visual interface, worn as glasses; 
and 
the rechargeable pocket processor 
worn around the waist. 
Figure 2 shows the retinal stimulator. 
It’s a complex implant comprising 2D 
or 3D electrode arrays, which connect 
to the ganglion cells; interconnects from 
the electrodes to the implant electron-
ics; implant electronics, including an 
ASIC for interpreting excitation pulses 
to individual electrodes; and IR power 
and data transmission.
The stimulator required a high-den-
sity array with individually address-
able electrodes that can provide suf-
ficient charge density to stimulate the 
ganglion cells.2 Figure 3 shows the 
platinum array designed by Intelligent 
Medical Implants (www.intmedim-
plants.de) and fabricated by ITE (www.
ite.waw.pl). The array has 234 indi-
vidually addressable electrode groups. 
Each group comprises a 3 × 3 array of 
truncated electrodes. Each electrode 
measures 60 × 60 µm to maximize the 
•
•
•
contact area on the ganglion cells. One 
block of 3 × 3 electrodes is 225 × 225 
µm, and the complete array, which is 
fixed to the retina, is approximately 
3,900 × 5,450 µm.
The retinal-stimulator electronics are 
located in the eye socket, and a biocom-
patible material encapsulates the entire 
implant.
The system’s visual interface inte-
grates a recording camera and image 
data transmission in a pair of glasses 
that connect to the pocket processor via 
cable. The pocket processor provides 
the power for the implant and on-the-
body unit. It also contains a processor 
that determines the excitation pulses 
for the image’s electrode array. The unit 
has programming capability from the 
PC via Ethernet.
The designed and fabricated system 
has successfully completed laboratory 
trials and is now undergoing human 
clinical trials at the Medical University 
of Graz.
Upper limb Fes implant
This FES application has two develop-
ment phases. In phase 1, FineTech Medi-
cal implemented the Stimugrip system 
(www.finetech-medical.co.uk/product-
hand.htm). It includes a control system 
that’s worn on the body, adjacent to the 
implant. The implant comprises two 
electrodes connected to passive electron-
ics. The system helps patients with an 
Glaucoma sensor
Retinal
implant
Activity monitor
Sphincter sensor
Bladder and bowel
electrical stimulators
Cochlear
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Intracranial pressure sensor
Functional
electrical
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for limb motion
Figure 1. Schematic of the final Healthy 
Aims project products. 
Figure 2. Retinal stimulator for the Healthy Aims retinal implant system. The 
electrode array is 4 × 5.5 mm, and the electronics is approximate 25 mm in diameter.
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upper motor neuron lesion extend their 
wrist and open the hand. 
Figure 4 shows the two parts: a pas-
sive, inductively powered, two-channel 
implanted stimulator and an external 
control unit. The external control unit 
incorporates batteries, an inductive coil 
that provides power to the implant, 
and control electronics. It also houses 
a three-axis accelerometer that detects 
arm movement. The accelerometer sig-
nals provide inputs to a state machine 
algorithm that determines the onset 
and termination of stimulation. Fine-
Tech Medical has developed software 
to automate and optimize the param-
eter setups for the state machine algo-
rithm.3 The patient wears the control-
ler unit on the affected limb, directly 
over the implant site. A strap secures 
it in place.
Phase 1 clinical trials are under way 
at the UK’s Salisbury District Hospi-
tal, and initial results on the first two 
patients are promising.
In phase 2, the project will implant 
the active components. This requires 
giving the implant its own power source 
and data communication system. The 
power source will be the secondary 
cell developed by Saft and the French 
Atomic Energy Commissariat (CEA) 
described later. An inductive coupling 
between the external charger and the 
implant will charge the cell overnight. 
The Medical Implant Communication 
Service (MICS), also described later, 
will control data communication for 
the active implant.
cochlear implant
Unlike the other products under 
development in Healthy Aims, implants 
for the profoundly deaf—namely, 
cochlear implants—already exist. 
Cochlear Limited has a system with 
22 electrodes that provides adequate 
resolution to understand speech in a 
quiet environment (www.cochlear.
com/Products/587.asp). The goal for 
Healthy Aims was to develop a tech-
nology that could support more stimu-
lation sites and, in combination with 
appropriate speech-processing strate-
gies, improve music appreciation and 
speech perception in noisy conditions. 
The consortium partners opted to build 
intracochlear electrodes that integrate 
with stimulation-site silicon chips and 
so bring the active stimulation circuitry 
to the inner cochlea. The interconnect 
technology is based on an intracochlear 
bus structure, which has the potential 
to increase the number of stimulation 
contacts significantly while eliminat-
ing the need for a separate, direct-wire 
connection from each stimulation site 
to the receiver-stimulator.
The fabrication process selected 
for these smart electrodes is based 
on wafer-level packaging techniques 
used in the semiconductor industry 
and developed by IMEC.4 The process 
integrates ASIC circuitry using wafer-
to-wafer bonding, followed by wafer 
thinning and deep-reactive-ion etching 
to separate the individual ICs. The ICs 
are subsequently interconnected by way 
of platinum tracks and embedded in 
multiple barrier layers made from plati-
num, Parylene-C, and silicone. These 
biocompatible materials prevent poten-
tially harmful materials from migrating 
into the cochlea fluid. They also keep 
moisture from damaging the IC.
Glaucoma sensor
Changes in eye pressure is one symp-
tom of the onset of glaucoma. The 
glaucoma sensor system noninvasively 
determines these changes for up to 24 
hours. It comprises a contact lens with 
an embedded strain gauge that detects 
changes in curvature caused by changes 
in eye pressure.5
The strain gauge and subsequent elec-
tronic circuitry for producing an ana-
log signal require power. The glaucoma 
sensor system uses a pair of spectacles 
and an associated body-worn unit to 
provide power over an inductively cou-
pled circuit running at 27.3 MHz. The 
same inductive link also transmits the 
225µm60µm
5,450µm
3,900µm
Figure 3. A 3D retina electrode array 
with 234 individually addressable 
electrode groups.
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analog signal. The body-worn power 
unit receives the signal and either stores 
the data for subsequent download and 
analysis or transmits it immediately via 
Bluetooth to a PC.
The consortium partners have now 
produced the first wireless contact lens 
version of the system, which is under-
going pilot clinical trials. It combines a 
50-µm-thick ASIC using the flip-chip 
attachment method, microfabricated 
strain gauges, and biocompatible coat-
ing materials. Considerable effort went 
into developing techniques for thin-
ning ASICs and attaching them to 
flexible membranes. Figure 5a shows 
the contact lens, and figure 5b shows 
the cross section of the ASIC assembly. 
Healthy Aims has applied and success-
fully demonstrated the thinning and 
flip-chip bonding techniques to not 
only the prototype glaucoma sensor but 
also the cochlear active implant and the 
ICP sensor system. The demonstration 
results show adequate compliance for 
these applications.
intracranial pressure   
sensor system
The ICP sensor system is suitable for 
short- or long-term monitoring of pres-
sure in the brain cavity.6 Short-term 
monitoring applies, for example, to 
people who have suffered head trauma 
in an accident and are in intensive care. 
Long-term monitoring applies to peo-
ple suffering with hydrocephalus who 
are treated with a shunt for draining 
excessive fluid. In the latter application, 
surgeons would place the ICP system in 
the brain cavity at the same time as the 
shunt. If the shunt gets blocked, it can’t 
remove the fluid and pressure therefore 
builds up in the brain. The sensor sys-
tem detects this pressure increase.
Because the system is aimed at short- 
and long-term implant applications, 
the pressure sensor must be extremely 
stable and safe over time. The consor-
tium partners have therefore completely 
encapsulated the implant with a bio-
compatible material and incorporated 
a stable, microfabricated, capacitive- 
pressure sensor and associated elec-
tronics. A separate, external RF reader 
powers the unit and receives the pres-
sure readings from the implant.
Figure 6 shows the implant. The 
very small pressure-sensor head (diam-
eter 3mm) is located in the brain cavity 
and connected to the RF communica-
tion electronics, both mounted on the 
same flexible substrate. The associated 
electronics and circuitry for inductive-
coupling power and data transmission 
are mounted on an enlarged part of the 
substrate, which is located outside the 
skull where space isn’t a limiting factor. 
The system receives its power from the 
handheld external reader and transmits 
data at 13.56 MHz (similar to RFID 
technology). Readings can be taken as 
often as required. This might be daily 
for long-term users, whereas it could be 
several readings per second for people 
in intensive care. The system can store 
data in the reader (an integrated data 
logger), or it can transmit data directly 
via ZigBee to a PC for further analysis.
Campus Micro Technologies (www.
campus-micro-technologies.de) has 
produced ICP prototypes, which have 
(b)(a)Figure 4. Upper-limb functional 
electrical stimulation system for 
restoring upper-limb movement:  
(a) implant electronics and electrodes 
and (b) external control unit. 
(b)
50 µm ASIC
Gold stud bump
Flexible substrate
(a)
Passive gauge
Active gauge
Antenna
ASIC
Figure 5. Glaucoma sensor (a) contact lens and (b) ASIC assembly.
Figure 6. Fully implantable wireless sensor for the intracranial pressure monitoring 
system.
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shown excellent stability over a 30-day 
period in lab trials. Thirty days is the 
critical performance requirement for 
short-term applications. Animal trials 
are now planned for the final year at 
the UK North Bristol National Health 
System’s Neurosurgery Department 
(www.nbt.nhs.uk/services/neurosci-
ences/neurosurgery.htm).
sphincter sensor
The sphincter sensor is used in a uro-
dynamics procedure to diagnose the 
cause for urinary incontinence. The 
sphincter sensor is inserted into the 
bladder and monitors dynamic blad-
der pressure over time. Currently, the 
urodynamics procedure involves force-
filling the bladder with water and mea-
suring pressure changes as the patient 
empties it. Future iterations of the 
product will enable an ambulatory test, 
which isn’t used regularly now because 
the cost is prohibitive. In the ambula-
tory test, the sensor remains in the body 
for 24 hours, measuring pressure as the 
patient fills and voids the bladder.
For both applications, the consortium 
partners have developed a low-cost 
microfabricated strain gauge mounted 
on a catheter. The strain gauge is fabri-
cated on an 8-µm film that is mounted 
in the catheter tip and deforms under 
pressure. Wires run from the sensor 
along the catheter where they interface 
into a data-logging unit.
Laboratory trials on the sensor 
assembly have shown that it achieves 
the required resolution of 1 cm of water 
with a maximum pressure of 1.5 m. 
It can also log data over the required 
24-hour period. Laboratory trials in a 
simulated bladder environment with the 
full catheter assembly and logging sys-
tem will take place within six months.
activity monitor
A growing body of research has linked 
physical inactivity to many common 
diseases such as cardiovascular disease 
hypertension, diabetes mellitus, and 
obesity. These studies typically rely on 
self-reported activity levels, but evidence 
suggests that this isn’t a reliable way to 
accurately quantify physical activity pat-
terns. In many cases, using an automated 
activity-monitoring system provides 
direct measurement of the type, intensity, 
and duration of activity over an extended 
period. Healthy Aims wanted to develop 
a measurement unit, together with a 
range of software for activity classifica-
tion and stride parameter estimation, 
that would improve on the performance 
of currently available systems. Current 
systems restricted specificity and, in 
some cases, required users to wear sen-
sors on multiple limb segments. 
European Technology for Business is 
a specialist microsystem design house 
that focuses on medical applications. 
ETB developed the activity monitor 
hardware in this project. It incorporates 
a three-axis accelerometer. It can run 
for up to 24 hours, storing data directly 
onto a memory card. At the activity’s 
end, the monitor downloads the data 
to the PC for analysis using algorithms 
developed within the project.
ETB has also developed algorithms 
for monitoring stride characteristics, 
including stride frequency and stride 
length, from a single waist-worn activ-
ity monitor. The University of Salford’s 
Healthy Aims group is developing algo-
rithms for classifying activity type on 
the basis of a nearest-neighbor tech-
nique. Initial results suggest that the 
adopted classification approach outper-
forms other similar approaches (for a 
review of accelerometry-based activity 
classification approaches, see Merryn 
Mathie and colleagues7). 
The University of Salford group has 
conducted trials on 10 healthy and 
10 obese subjects. The trial protocol 
included a period on the treadmill 
followed by a range of outdoor activi-
ties including hopping, stair climbing, 
walking, jogging, and running. Par-
ticipants wore monitors on their waist, 
thighs, and shanks to enable a system-
atic appraisal of how the number and 
location of monitors affected algorithm 
performance.
Key technologies
Developments in three core tech-
nologies supported the Healthy Aims 
products. 
implantable battery
The requirements for implant power 
sources are extremely challenging. Saft 
and the CEA designed a 50 mAh pris-
matic rechargeable lithium-ion cell that 
meets these requirements in a range of 
TABLE 1 
 Implantable lithium-ion battery characteristics.
Characteristic Performance metric
Operating	temperature 37˚C
Dimensions <	5	×	10	×	22	mm
Weight 2.45	g
Capacity 50	mAh
Lifetime	at	37˚C >	10	yrs
Number	of	charges/discharges* >	4,000
Autonomy 16–20	hrs
Minimum	charge	time 2	hrs
Voltage	window 3.0–4.0	V
Maximum	continuous	discharge	current 10	mA
Maximum	pulse	(1000	µs)	current 50	mA
* 100% depth of discharge, with more than 50% of initial capacity remaining.
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nonvital medical-device applications. 
In addition to high energy density and a 
proven record of long cycle and calendar 
life, the battery meets the key require-
ment of not significantly raising the body 
tissue temperature while charging. Table 
1 lists some of its detail characteristics.
Healthy Aims selected it for the 
cochlear implant and FES systems. 
Work is now under way to integrate 
the battery and charging circuit 
into the implant enclosure for these 
applications.
biofuel cell
Some implant applications—for 
example, a pacemaker—have low 
enough power requirements to use for 
a biofuel cell. Healthy Aims has devel-
oped a direct biofuel cell that derives 
electricity directly from body fluids. 
Specifically, it uses the spatially sepa-
rated electrochemical reaction of glu-
cose and oxygen.
The cell has a selective cathode 
consisting of activated carbon that’s 
arranged in front of the anode.8 The 
carbon effectively depletes oxygen 
inside the fuel cell, and glucose oxida-
tion takes place under predominantly 
anoxic conditions. This concept 
enables the fuel cell to be mounted 
directly on the surface of medical 
implants, facilitating system integra-
tion and implantation.
Figure 7 shows the cell’s construc-
tion. The electrode dimensions are 
1.5 cm × 1.5 cm. To increase electrical 
conductivity, both electrodes include a 
platinum-mesh electron collector. Plati-
num wires establish electrical connec-
tions to the electron collector with con-
ductive carbon cement. The electrodes 
are electrically insulated by a glucose-
permeable membrane. An epoxy resin 
casing gives structural stability to the 
membrane electrode assembly.
The consortium partners, University 
of Freiburg (imtek) and University of 
Rovira i Virgili (Dinamic), character-
ized the fuel cell’s electrochemistry in 
tests carried out at 37ºC in 600 ml of 
aerated phosphate-buffered saline solu-
tion (pH 7.4) containing 0.1 percent 
glucose by weight (the appoximate con-
centration of human interstitial fluid). 
A stable power output of 1.5 µW/cm² 
was observed after 200 days, with a 
corresponding cell voltage of 112 mV. 
The results demonstrate that a 3 cm × 
3 cm biofuel cell, applied to the surface of 
an implant, would be sufficient to power 
an 8 µW pacemaker circuit. The con-
cept thus shows promise for developing 
autonomous, sustainable power supply 
systems for long-term medical implants.
Wireless communication
Because implanted devices must be 
completely self-contained, the data trans-
fer method from inside the body must 
be wireless. Application requirements 
and medical safety standards define the 
data-transfer carrier frequency.
RF technology supports suitable wire-
less links between implants and body-
worn units when power is available 
within the implant. For Healthy Aims’ 
FES and cochlear-implant projects, 
Zarlink has integrated a wake-up func-
tion into a medical-implant RF trans-
ceiver (http://assets.zarlink.com/PP/
ZL70101_Product_Preview_0907.pdf). 
The wake-up function leaves the RF cir-
cuit turned off for most of the time.
The frequency assigned for implanted- 
device RF communication is around 
403 MHz and referred to as the MICS 
(Medical Implant Communication Sys-
tem) band.
The 2.4 to 2.5GHz ISM (Industrial 
Scientific and Medical) band is suitable 
for transmitting to an implant but not 
from it. Transmitting the wake-up signal 
to an implant on the ISM band requires 
less current in the receiver design than 
transmitting on the MICS band would. 
The average current consumption de-
creases further if the receiver is only 
switched on for short periods of time 
at predetermined intervals. If the strobe 
frequency is once per second with an on 
time of 240 ns, the wake-up receiver’s 
average current is typically 200 nA.
Once the implant receives a valid 
wake-up signal, the remainder of its 
implant RF circuit can be powered up 
within 20 ms. The transceiver remains 
powered for the duration of the inter-
rogation and then shuts off until it 
receives another wake-up signal. In 
this way, the communication circuit 
uses significant current only during 
data transfers.
Transferring the data at a high speed 
further minimizes the wake-up time 
for the implant transceiver. Typically, a 
raw data rate of 200 Kbps to 800 Kbps 
is possible.
(b)(a)
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Figure 7. Schematic diagrams of a 
surface-mountable glucose biofuel cell:  
(a) cross section and (b) magnified  
view of the electrode structure.
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Zarlink has integrated the MICS chip 
into two FES implants, one for upper 
arm movement and the other for blad-
der control. University College London 
and Finetech Medical are now working 
to integrate the chip and antenna into 
the implant enclosure. Figure 8 shows 
a demonstrator, now available from 
Zarlink, that includes a processor to 
prove the communication link. For 
more details on this project, see Body 
Sensor Networks, chapter 4.
biocompatible implant coatings
All implants will be completely encap-
sulated with a biocompatible material 
to prevent leaching from implant com-
ponents to the body and to stop water 
ingress to the components. These bio-
compatible coatings must remain stable 
for the implant’s lifetime, which in 
many cases can be the same as a per-
son’s lifetime. Healthy Aims researchers 
at Queen Mary, University of London 
have been working with the implant 
product partners to develop biocom-
patible coatings that are thin, flexible, 
and rugged enough for handling during 
surgery.9 Preliminary results using lipid-
modified silicone and diamond-like car-
bon (DLC) indicate that these materials, 
both together and individually, could 
meet the mechanical requirements and 
improve the water resistance compared 
to silicone alone.10
Applying DLC as a very thin coating 
(100 nm or less) directly on a sensor’s 
surface doesn’t significantly affect per-
formance. It can also be applied as a 
sandwich layer with conventional mate-
rials such as Parylene-C or silicone.
C ollectively, the Healthy Aims project has stimulated the development of medi-cal implant and diagnostic 
equipment. Human clinical trials are 
now successfully underway for the 
two-channel, upper-arm FES system 
as well as the glaucoma sensor and the 
activity monitor. Acute animal trials on 
the FES system for bowel control have 
concluded successfully, and plans for 
chronic trials are underway. Labora-
tory trials for the cochlear implant’s 
active electrodes have begun, and 
Cochlear Technology Centre has suc-
cessfully concluded initial trials on the 
prototype implant battery. 
The core technologies developed to 
support these and other Healthy Aims 
projects will further advance this grow-
ing field of medical technology.
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